secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lite Strategy, Inc. (LITS)
CIK:        0001262104
Form:       8-K
Filed at:   2025-02-12T23:59:59+00:00
Accession:  0000950170-25-018820
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MEI Pharma reports $23.7M cash, no debt, continues strategic alternatives review
--------------------------------------------------------------------------------

- Cash and cash equivalents $23.7M as of Dec 31, 2024; no outstanding debt.
- Strategic alternative evaluation ongoing, including out-licensing and M&A; Oppenheimer & Co. as financial advisor.
- Cash preservation efforts underway, including staged reduction-in-force.
- No assurance that the strategic review will result in any transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1262104/000095017025018820/0000950170-25-018820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1262104/000095017025018820/meip-20250212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-018820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer